跳转至内容
Merck
CN

MAB3757

Sigma-Aldrich

Anti-VEGF Receptor-3 Antibody, extracellular domain, clone 9D9F9

ascites fluid, clone 9D9F9, Chemicon®

别名:

VEGFR3, VEGFR-3, Receptor tyrosine Kinase VEGFR-3

登录查看公司和协议定价

选择尺寸


关于此项目

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

mouse

抗体形式

ascites fluid

抗体产品类型

primary antibodies

克隆

9D9F9, monoclonal

种属反应性

human

制造商/商品名称

Chemicon®

技术

flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

同位素/亚型

IgG1

UniProt登记号

运输

wet ice

靶向翻译后修饰

unmodified

基因信息

human ... VEGFA(7422)

一般描述

175 kDa
Vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligands, vascular endothelial growth factor-C (VEGF-C) and -D (VEGF-D), are the major molecules involved in developmental and pathological lymphangiogenesis. {Bando, 2004}. Jussila et al reported that VEGFR3 antibodies specifically stain endothelial cells of lymphatic vessels and vessels around tumonrs such as lymphoma and in situ breast carcinoma. {Jussila, 1998}.Interestingly, the spindle cells of several cutaneous nodular AIDS-associated Kaposi′s sarcomas and the endothelium around the nodules were also VEGFR-3 positive. The first specific molecular marker for the lymphatic endothelium should provide a useful tool for the analysis of lymphatic vessels in malignant tumors and their metastases and the cellular origin and differentiation of Kaposi′s sarcomas. {Jussila, 1998}.

免疫原

Recombinantly produced, purified, hVEGFR-3 extracellular domain protein from baculovirus culture {Jussila, 1998}.

应用

Anti-VEGF Receptor-3 Antibody, extracellular domain, clone 9D9F9 is an antibody against VEGF Receptor-3 for use in FC, IF, IH(P), IP & WB.
Immunohistochemistry: frozen cryosections, 5μm cryosections were air-dried and fixed in cold acetone for 10 minutes. Blocked with 5% normal horse serum and then incubated with 9D9 for 2 hours at room temperature in a humid chamber. Typical dilutions will range from 1:100-1:1000 depending upon lot titer. Detection is with enhanced methods (ABC or poly HRP) and enzymatic substrates for best results.

Immunohistochemistry in paraffin: 5μm thick lightly fixed formalin tissues were processed through decreasing ethanol concentrations, washed with water, then heated in a microwave in 10mM sodium citrate pH 6.0 at 780W for 5 minutes, followed by 450W for 10 minutes. The sections were then incubated in methanol containing 30% hydrogen peroxide for 30 minutes and processed further like the cryosections. {Jussila, 1998}.

Western Blot: antibody recognizes VEGFR-3 on reduced samples of HUVEC and HDMEC cells {primay human umbilical vein endothelial cells & primary human dermal microvascular endothelial cells}. The bands seen at molecular weight 195kDa and 125kDa represent the uncleaved and proteolytically cleaved forms of VEGFR3. The band at 175kDa is considered to be intracellular, unglycosylated precursor {Bando, 2004}.

Immunoprecipitation: 1-5μL per 300-500μL of cell lysate. Use protein A or rabbit anti-mouse IgG capture for best results.

ELISA: 9D9F9 has been used as the detection antibody for a VEGFR-3 ELISA {Bando, 2004}.

Flow Cytometry: reactive on transfected NIH-3T3 cells expressing hVEGFR3, Other cell lines untested. {Jussila, 1998}.

Optimal dilutions will need to be determined by the enduser.

生化/生理作用

Specific for human VEGFR-3. Western blot and ELISA demonstrate that the antibody is highly specific for VEGFR-3 with no cross-reactivity with human VEGFR-1 or VEGFR-2 protein {Bando, 2004}. Cross reactivity with other species VEGFR-3 proteins untested.

外形

UnPurified ascites fluid containing 0.1% sodium azide as a preservative.

分析说明

Control
Human lymphatic tissues

VEGFR-3 is not expressed in HEVs of the lymph nodes. {Jussila, 1998]. In lymphomas staining is seen mostly in collapsed vessels in the cortex of lymph nodes infiltrated by the lymphoma cells. The antibody specifically detects lymphatic endothelium in human lymph node and other organs such as tonsil. See Jussila et al, 1998 for complete tissue characterization.

其他说明

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

12 - Non Combustible Liquids

WGK

nwg

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sirpa Loukovaara et al.
Acta ophthalmologica, 93(6), 512-523 (2015-04-23)
Proliferative diabetic retinopathy (PDR) is characterized by ischaemia- and inflammation-induced neovascularization, but the pathological vascular differentiation in PDR remains poorly characterized. Here, endothelial progenitor and growth properties, as well as potential lymphatic differentiation, were investigated in the neovascular membrane specimens
Dieter Zopf et al.
Cancer medicine, 5(11), 3176-3185 (2016-10-14)
Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment-refractory metastatic colorectal cancer.
Dariush Moussai et al.
The Journal of investigative dermatology, 131(1), 229-236 (2010-09-10)
Metastases from primary cutaneous squamous cell carcinoma (SCC) account for the majority of the ∼10,000 non-melanoma skin cancer deaths in the United States annually. We studied lymphangiogenesis in human SCC because of the potential link to metastasis. SCC samples were
Laura Dupont et al.
JCI insight, 7(8) (2022-03-23)
The capacity of ADAMTS3 to cleave pro-VEGFC into active VEGFC able to bind its receptors and to stimulate lymphangiogenesis has been clearly established during embryonic life. However, this function of ADAMTS3 is unlikely to persist in adulthood because of its
Denis Tvorogov et al.
Cancer cell, 18(6), 630-640 (2010-12-07)
Antibodies that block vascular endothelial growth factor (VEGF) have become an integral part of antiangiogenic tumor therapy, and antibodies targeting other VEGFs and receptors (VEGFRs) are in clinical trials. Typically receptor-blocking antibodies are targeted to the VEGFR ligand-binding site. Here

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持